Company Insights

GSBD customer relationships

GSBD customer relationship map

Goldman Sachs BDC (GSBD): Customer Relationships That Drive Yield and Credit Risk

Goldman Sachs BDC Inc. (GSBD) operates as a closed‑end business development company that originates and acquires middle‑market debt and equity positions and monetizes through interest income, fee income on financings and a distribution policy designed to deliver steady cash yield to shareholders. The company leverages Goldman Sachs Asset Management’s private credit platform to source long‑duration, secured credits primarily to U.S. middle‑market firms, and selectively co‑invests equity when sponsorship economics justify it. For investors, GSBD’s customer mix is a direct read on portfolio concentration, credit staging and the firm’s active engagement as a managerial lender. Learn more about how these signals map to credit and yield for portfolios at Null Exposure.

What the customer roster reveals about how GSBD operates

GSBD’s documented relationships and internal constraints paint a coherent operating model: long-term credit exposures to North American middle‑market companies, with a meaningful tilt to software and services sectors and active portfolio management. Key company-level signals:

  • Contracting posture — long-term: GSBD targets maturities of three to ten years and typically sizes investments between $10 million and $75 million or larger, signaling sizable, multi‑year exposures that create duration and credit risk.
  • Counterparty profile — mid‑market: The company explicitly targets U.S. middle‑market enterprises (EBITDA roughly $5M–$200M), which increases idiosyncratic credit risk but also yields spread pickup versus larger corporate borrowers.
  • Geographic concentration — North America: Approximately 97% of fair value sits in the U.S., producing country risk concentration and sensitivity to U.S. rates and economic cycles.
  • Role and engagement — managerial lender: As a BDC, GSBD provides managerial assistance and active monitoring, indicating higher touch relationships that can protect recoveries but also require operational bandwidth.
  • Sector tilt and spend band: Software and healthcare services are notable portfolio sectors; typical investment sizes fall in the $10M–$100M band, consistent with meaningful individual position risk and potential concentration effects.

These characteristics combine to create a credit portfolio that is illiquid, concentrated sector‑wise, and reliant on active credit workout capability — strengths for yield generation, and risks if macro or sector shocks accelerate losses. If you want a concise briefing that maps customer relationships to credit exposure and recovery scenarios, visit Null Exposure.

Deal-by-deal: what each customer relationship tells investors

mPulse Mobile, Inc.

GSBD’s 2024 Form 10‑K records the sale of Zodiac Intermediate, LLC (doing business as Zipari) to mPulse Mobile, Inc., categorized as a non‑income producing sale in FY2024. This disclosure reflects portfolio realizations and occasional disposal of non-core positions as part of portfolio management (GSBD 2024 Form 10‑K).

Shields Health Solutions

Management highlighted the strategic value of the Goldman Sachs franchise when financing the acquisition of Shields Health Solutions, indicating GSBD participation in sponsor-led transactions where GS distribution and origination capabilities are additive to deal execution (Q3 2025 earnings call transcript reported on InsiderMonkey).

Newtek Merchant Solutions (NEWT)

GSBD financed Newtek Merchant Solutions — a payments and financial services platform — supporting a sponsor or corporate activity; Newtek is the publicly traded bank holding company parent. This underscores GSBD’s willingness to back financial‑services businesses within its middle‑market remit (Q3 2025 earnings call transcript via InsiderMonkey; Newtek ticker NEWT referenced by management).

Total Vision

Total Vision — an operator of optometry practices — was originally financed by GS in 2021, with GSBD receiving full repayment of the credit facility and equity co‑investment at payoff. This transaction illustrates portfolio turnover and the potential for realized gains when sponsor‑led rollups mature (Q3 2025 earnings call transcript on InsiderMonkey).

KUIU

In Q4 2025 GSBD acted as sole lead arranger on the acquisition financing for KUIU, an e‑commerce apparel brand focused on outdoor consumers, demonstrating GSBD’s role as a lead arranger on middle‑market consumer and branded retail deals (Q4 2025 earnings call transcript summarized on InsiderMonkey).

Pluralsight

As of December 31, 2025, GSBD placed its first‑lien/senior secured debt position in Pluralsight on non‑accrual, signaling realized credit stress in a software portfolio holding and spotlighting potential near‑term loss provisioning or restructuring activity (Q4 2025 earnings call transcript reported on InsiderMonkey).

Dental Brands

Management disclosed a new credit investment placed on non‑accrual at Dental Brands, indicating active credit deterioration within the healthcare provider segment and the need to assess recovery prospects in platform consolidations (Q3 2025 earnings call transcript via InsiderMonkey).

Clearwater Analytics (CWAN)

GSBD disclosed that Goldman Sachs was a customer of Clearwater across several divisions, and that the GS Private Credit complex initially committed 100% of a $3.5 billion unitranche financing for the take‑private of Clearwater by sponsors; GS retained $1.235 billion of the facility and GS BDC owned $75 million at closing — a sizeable sponsored financing allocation by GSBD into a single private credit sponsor transaction (GSBD Q4 2025 earnings call; related reporting on InsiderMonkey).

How these relationships translate to investor risk/reward

Collectively, these customer interactions reveal several actionable investor implications:

  • Concentration risk: Large single‑deal allocations (e.g., $75M Clearwater stake) and sector concentrations in software and services create idiosyncratic risk that can skew quarterly volatility.
  • Active credit cycle exposure: Multiple non‑accruals (Pluralsight, Dental Brands) confirm the portfolio is cycling through credit workouts, increasing near‑term provisioning needs but also providing opportunities for recoveries via active managerial intervention.
  • Sponsor and franchise leverage: GS’s platform enhances deal flow and structuring, which is a competitive advantage when underwriting complex take‑privates and sponsor deals (e.g., Shields, Clearwater, KUIU).
  • Duration and liquidity profile: Long maturities and mid‑market underlyings produce yield premium but also mark‑to‑market sensitivity and limited secondary liquidity.

These dynamics make GSBD an income‑oriented vehicle where credit selection and GS’s origination advantage are primary return drivers; downside is concentrated credit and U.S. cyclical exposure.

What research and operations teams should do next

  • Prioritize monitoring of existing non‑accruals for workout outcomes and recovery expectations; Pluralsight and Dental Brands require immediate attention.
  • Stress test portfolio concentration by sector and individual position size, particularly the Clearwater exposure and any single‑name holdings over the $50M band.
  • Validate operational capacity for managerial assistance across healthcare and software platform companies, since that engagement is a stated BDC obligation.

For a structured examination of GSBD’s customer footprint and implications for credit risk modelling, consult the team at Null Exposure.

Bottom line

GSBD monetizes through long‑dated, middle‑market credit investments backed by Goldman Sachs’ origination and sponsor relationships. The customer list shows both the upside of sponsor‑led financings and the downside of active non‑accruals. Investors should weigh GSBD’s yield profile against meaningful single‑name and sector concentration risk, and track near‑term workout outcomes for a clearer picture on NAV trajectory. For detailed mapping between customer relationships and portfolio stress scenarios, visit Null Exposure.